Recent Comments

Comment RSS

Pulmonary Arterial Hypertension News and Research RSS Feed - Pulmonary Arterial Hypertension News and Research

Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.

Pfizer’s Revatio Injection receives FDA approval

20. November 2009 09:18
Pfizer announced today that the U.S. Food and Drug Administration (FDA) has approved Revatio® (sildenafil) Injection, an intravenous formulation of Revatio. Revatio is the only FDA-approved phosphodiesterase-5 (PDE5) inhibitor available in both tablet and intravenous formulations. [More]

Early diagnosis and treatment is crucial for pulmonary hypertension, a rare but deadly disease

19. November 2009 06:56
We often hear about the perils of high blood pressure, but many Canadians are unaware that high blood pressure in the lungs - known as pulmonary hypertension (PH) - can also have fatal consequences. This month, the Pulmonary Hypertension Association of Canada hopes to raise awareness about PH - a rare but serious disease that can strike at any time and has no regard for race, age or gender. [More]

Once-a-day dosing clinical study of udenafil for erectile dysfunction completed

19. November 2009 00:44
Dong-A Pharmaceutical Co., Ltd. and Dong-A PharmTech, Co. Ltd. announced today that it has completed a 240 patient once-a-day dosing clinical study of udenafil, its new long acting phosphodiesterase type 5 (PDE-5) inhibitor for erectile dysfunction (ED). [More]

Ambrisentan improves health and exercise capacity of PAH patients, find researchers

18. November 2009 05:24
In one of the few studies of the long-term effects of medication in the treatment of pulmonary arterial hypertension (PAH) disease, a team of researchers found the health and exercise capacity of PAH patients improved after two years of treatment with ambrisentan, according to a study published in the current edition of the Journal of the American College of Cardiology. [More]

Non-clinical data from Cytokinetics' smooth muscle contractility program presented

17. November 2009 08:27
Cytokinetics, Incorporated announced today that three abstracts summarizing non-clinical data regarding its smooth muscle contractility program were presented at the 2009 Scientific Sessions of the American Heart Association in Orlando, Florida. [More]

Proteo's Elafin recommended for orphan drug status in Europe

16. November 2009 05:24
The Committee for Orphan Medical Products (COMP) of the European Medicines Agency (EMEA) has issued a recommendation granting orphan drug status to Proteo's drug candidate Elafin for the treatment of esophagus carcinoma. The orphan drug status will become effective upon ratification of this recommendation by the European Commission. [More]

Warner Chilcott initiates phase III trial of erectile dysfunction drug udenafil

4. November 2009 23:47
Dong-A PharmTech Co. Ltd., announced that its U.S. partner, Warner Chilcott plc, has initiated two, phase III trials for udenafil, a new long acting drug under development for erectile dysfunction (ED). Each randomized, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of udenafil, an orally administered selective inhibitor of phosphodiesterase versus placebo. [More]

PAH patients face life-threatening risks from medication errors

4. November 2009 08:26
Pulmonary arterial hypertension (PAH) patients using infused drugs have suffered serious injury or in some cases died from medication errors in hospitals and other inpatient settings, according to a peer-reviewed study by Accredo Health Group and several university hospitals that surveyed doctors, nurses and pharmacists. [More]

Study of combination therapy versus monotherapy for pulmonary arterial hypertension

2. November 2009 10:11
Gilead Sciences, Inc., in collaboration with GlaxoSmithKline (GSK), today announced plans for an international, event-driven (morbidity and mortality) clinical trial to study combination therapy versus monotherapy in a first-line treatment setting for pulmonary arterial hypertension (PAH). [More]

Third quarter 2009 financial results announced by United Therapeutics

29. October 2009 07:37
United Therapeutics Corporation (Nasdaq: UTHR) today announced its results of operations for the quarter ended September 30, 2009. [More]

Posted in: Business / Finance

Tags: , , , ,

Accredo Health Group announces a 10-year renewal of its headquarters with Memphis

22. October 2009 08:39
Accredo Health Group Inc. announced a 10-year renewal of its 240,000-square-foot headquarters at Century Center, positioning the nation's largest specialty pharmacy and a major fixture of Memphis' health care industry for future growth. The General Investment & Development Companies and Accredo agreed to renew all leases for Accredo's five-building campus, effective January 1, 2010. [More]

Arginetix raises funds for development programs

2. October 2009 23:52
Arginetix, Inc. today announced it has closed a $10.75 million Series A financing. The company is developing small molecule inhibitors of the enzyme arginase for the treatment of endothelial dysfunction, including pulmonary arterial hypertension, atherosclerosis and asthma. [More]

Endothelin research update to be presented at APS' 11th International Conference

10. September 2009 23:12
Recent research to block the effects of endothelin, a powerful substance that constricts blood vessels and stimulates cell growth, has led to successful treatment of pulmonary arterial hypertension and provides hope for treating other chronic diseases. [More]

Positive impact on medication adherence through Aetna's care management program

4. September 2009 02:18
Aetna announced today results of an analysis from the first half of 2009, demonstrating an average medication adherence of over 95 percent for its members taking Specialty medications. Disease states evaluated in Aetna’s analysis include: multiple sclerosis, rheumatoid arthritis, HIV, Crohn's disease, Pulmonary Arterial Hypertension (PAH), psoriasis, Hepatitis C and asthma. [More]

Actelion launches new 20 mcg/mL Ventavis formulation

2. September 2009 04:12
Actelion Pharmaceuticals US, Inc., today announced the first commercial sales of a new 20 microgram per milliliter (mcg/mL) formulation of Ventavis(R), for the treatment of New York Heart Association Class III and IV pulmonary arterial hypertension (PAH). This increased strength formulation delivers the same dose of Ventavis in half the volume, which is expected to reduce inhalation time and further support patient compliance. [More]
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.